市場調査レポート

商品コード

1619181

肝がん治療薬の市場規模、シェア、成長分析、薬剤別、タイプ別、流通チャネル別、地域別 - 産業別予測、2024～2031年

Liver Cancer Drugs Market Size, Share, Growth Analysis, By Drug (Targeted Therapy, Immunotherapy), By Type (Hepatocellular Carcinoma, Cholangio Carcinoma), By Distribution Chanel, By Region - Industry Forecast 2024-2031

出版日: 2024年12月19日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 779,047円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 911,338円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,043,629円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
目次

概要

サンプル依頼リストに入れる

肝がん治療薬の世界市場規模は、2022年に29億8,000万米ドルと評価され、2023年の35億1,000万米ドルから2031年には131億2,000万米ドルに成長し、予測期間中（2024-2031年）のCAGRは17.9％で成長する見通しです。

肝臓がん治療分野の市場成長は、新薬の利用可能性の増加、強固なパイプライン、一般市民の意識の高まりが原動力となっています。特に、不健康な生活習慣を持つ高齢者の間で肝がんの罹患率が上昇していることが、この成長をさらに後押ししています。肝細胞がん（HCC）は原発性肝がんの75～90％を占める。肝炎感染や肝硬変など多くの危険因子は修正可能であり、生活習慣の改善や肝炎ワクチン接種などの予防戦略の機会を提供しています。地理的には、北米と南欧州で肝がんによる死亡率が最も高く、東アジアでは男性（10万人当たり31.9人）と女性（10万人当たり10.2人）の罹患率が最も高いです。このことは、的を絞った介入や治療が必要な重要な地域を浮き彫りにしています。

北米
- 米国
- カナダ
欧州
- 英国
- ドイツ
- スペイン
- フランス
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2023年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2021-2023）

主要企業プロファイル

Exelixis, Inc.
Merck KGaA
Bristol-Myers Squibb Company
Bayer AG
Thermo Fisher Scientific Inc.
Pfizer Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Novartis AG
Abbott Laboratories
Gilead Sciences
Zydus Pharmaceuticals Inc
AbbVie Inc.
Johnson & Johnson Services Inc.

結論と推奨事項

Product Code: SQMIG35B2174

Global Liver Cancer Drugs Market size was valued at USD 2.98 billion in 2022 and is poised to grow from USD 3.51 billion in 2023 to USD 13.12 billion by 2031, growing at a CAGR of 17.9% during the forecast period (2024-2031).

Market growth in the liver cancer treatment sector is driven by increased availability of novel drugs, robust pipelines, and heightened public awareness. The rising incidence of liver cancer, particularly among the aging population with unhealthful lifestyles, is further propelling this growth. Hepatocellular carcinomas (HCCs) represent 75-90% of primary liver cancer cases. Many risk factors, such as hepatitis infection and cirrhosis, are modifiable, presenting opportunities for preventive strategies like lifestyle changes and hepatitis vaccination. Geographically, North America and Southern Europe experience the highest mortality rates for liver cancer, while Eastern Asia shows the most significant incidence rates for males (31.9 per 100,000) and females (10.2 per 100,000). This highlights critical areas for targeted interventions and treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cancer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cancer Drugs Market Segmental Analysis

Global Liver Cancer Drugs Market is segmented by Drug, Type, Distribution Chanel, and region. Based on Drug, the market is segmented into Targeted Therapy, Immunotherapy, and Chemotherapy. Based on Type, the market is segmented into Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, and Others. Based on Distribution Chanel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Cancer Drugs Market

The global market for liver cancer drugs is driven by the alarming rise in liver cancer cases, which sees around one million new diagnoses annually worldwide. The increasing number of smokers and alcohol consumers, alongside urbanization, significantly contributes to liver-related health issues. Government initiatives and investments from global healthcare organizations further bolster the growth of this market. Moreover, the emergence of innovative liver cancer medications and a rise in FDA approvals specifically targeting hepatocellular carcinoma-which represents nearly 90% of liver cancer cases-reflects heightened research and development efforts to combat this critical disease, indicating a promising future for the industry.

Restraints in the Global Liver Cancer Drugs Market

The Global Liver Cancer Drugs market faces significant constraints that could impede its growth trajectory. Key among these are stringent regulatory requirements imposed by governments, which may hamper the approval process for numerous small molecules and biologics in developed nations. As a result, products that are not equipped with cutting-edge technology may encounter elevated rates of processing errors, compromised quality, and heightened cost challenges. These factors collectively pose obstacles for market expansion, potentially leading to reduced access and limited options for patients and healthcare providers. Consequently, the overall potential for growth within this therapeutic market may be significantly affected.

Market Trends of the Global Liver Cancer Drugs Market

The Global Liver Cancer Drugs market is experiencing a significant upward trend, largely driven by robust research and development initiatives aimed at enhancing treatment outcomes. With an emphasis on prolonging patient survival and improving quality of life, pharmaceutical companies are increasingly focusing on innovative approaches such as immunotherapy and targeted therapies. Collaborative efforts, exemplified by partnerships like that between Sirnaomics and Innovent Biologics for clinical research on Tyvy and STP705, are accelerating advancements in liver cancer treatment. This strategic alliance and others like it are not only propelling clinical progress but also expanding the market's potential, thereby positioning the sector for sustained growth and investment.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies

Global Liver Cancer Drugs Market Size by Drug & CAGR (2024-2031)

Market Overview
Targeted Therapy
Immunotherapy
Chemotherapy

Global Liver Cancer Drugs Market Size by Type & CAGR (2024-2031)

Market Overview
Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Others

Global Liver Cancer Drugs Market Size by Distribution Chanel & CAGR (2024-2031)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global Liver Cancer Drugs Market Size & CAGR (2024-2031)

North America (Drug, Type, Distribution Chanel)
- US
- Canada
Europe (Drug, Type, Distribution Chanel)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific (Drug, Type, Distribution Chanel)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America (Drug, Type, Distribution Chanel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug, Type, Distribution Chanel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Exelixis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

肝がん治療薬の市場規模、シェア、成長分析、薬剤別、タイプ別、流通チャネル別、地域別 - 産業別予測、2024～2031年

Liver Cancer Drugs Market Size, Share, Growth Analysis, By Drug (Targeted Therapy, Immunotherapy), By Type (Hepatocellular Carcinoma, Cholangio Carcinoma), By Distribution Chanel, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

肝がん治療薬市場規模：薬剤別

肝がん治療薬市場規模：タイプ別

肝がん治療薬市場規模：流通チャネル別

肝がん治療薬市場規模：地域別